Kapizen

Lercanidipine Hydrochloride, the active ingredient in Kapizen, is a calcium channel blocker presented as an oral tablet for oral use. It treats hypertension in adult patients and is indicated for the management of elevated blood pressure, typically administered once daily.

GNH USA supplies Kapizen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory‑aligned distribution for healthcare providers seeking quality antihypertensive medicines. The company adheres to stringent quality standards and offers comprehensive support throughout the procurement process.

Lercanidipine is used in the management of hypertension, a condition characterized by chronically elevated arterial pressure.

Hypertension: Reduces systolic and diastolic blood pressure, helping to lower cardiovascular risk. Essential hypertension: Lowers blood pressure in patients with primary hypertension. Isolated systolic hypertension: Improves systolic pressure control in elderly patients.

Lercanidipine may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: Mild to moderate intensity, often transient. - Flushing: Warm sensation and reddening of the skin. - Peripheral edema: Swelling, usually of the ankles or lower legs. - Dizziness or light‑headedness, especially after standing. - Tachycardia or palpitations. - Gastrointestinal discomfort such as nausea.

Serious or Rare Side Effects: - Severe hypotension: Marked drop in blood pressure requiring medical attention. - Angioedema: Swelling of face, lips, tongue, or throat. - Hepatic dysfunction: Elevated liver enzymes or hepatitis. - Myocardial infarction: Rare occurrence of heart attack. - Allergic reactions: Rash, itching, or anaphylaxis.

When prescribing lercanidipine, clinicians should consider several safety measures.

Blood pressure monitoring: Check regularly to assess therapeutic response and avoid excessive hypotension. Liver function: Evaluate hepatic enzymes before initiating therapy and periodically during treatment. Elderly patients: Start at low dose and monitor for edema and dizziness. Concomitant antihypertensives: Adjust doses to prevent additive blood pressure lowering. Pregnancy and lactation: Use only if clearly needed after risk‑benefit assessment. Store at room temperature: Keep in original container, protect from moisture and light.

Lercanidipine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, erythromycin): May increase plasma levels and risk of hypotension. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): May reduce drug exposure and effectiveness. - Concomitant use with other potent antihypertensives (e.g., clonidine, nitroglycerin): May cause additive hypotensive effects.

Moderate Interactions (Monitor Closely): - Grapefruit juice: Can increase lercanidipine exposure; advise moderation. - Diuretics: May enhance antihypertensive effect and alter electrolytes; monitor renal function. - Beta‑blockers: May increase risk of bradycardia; observe heart rate.